Tag Archives: Kovaltry

March, 2016

  • 17 March

    FDA Approves Bayer’s Long-Acting Hemophilia Drug

    WHIPPANY, N.J., March 17, 2016 /PRNewswire/ — The U.S. Food and Drug Administration has approved Bayer’s KOVALTRY®Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based on results from the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia …